Young MM patients (< 60 years) who have not received much treatment previously (≥ three lines) and do not have high-risk genetic characteristics (t (4; 14), t (14; 16), t (14; 20), del (17p), +1q and p53 mutation) or extramedullary diseases would benefit most from CAR-T therapy [7, 8]. The gene discussed is TP53; the disease is Miyoshi myopathy.